Clinical trials: Adverse Effect of Thrombolytic Drugs
Stroke, Acute, Drug Toxicity
Outcome of Patients Treated by iv Rt-PA for Cerebral Ischaemia According to the Ratio Sc-tPA/Tc-tPA
intravenous rt-PA is effective to reduce the risk of death or dependency after ischaemic stroke. This effect is due to an early recanalization secondary to the lysis of the clot.
- Trial name
- OPHELIE (NCT01614080)
- Where
- France
- Volunteers
- 700 people
- Sponsor
- University Hospital, Lille
Intracranial Hemorrhages, Stroke
Risk of Intracranial Hemorrhage in Users of Oral Antithrombotic Drugs
The true incidence and risks of intracranial hemorrhage (ICH) in patients on various antithrombotic treatments remain unknown. Here a nationwide study is conducted to investigate the risk for and incidence rates of ICH in users…
- Trial name
- RICH (NCT02481011)
- Testing
- antithrombotic drugs
- Where
- Norway
- Volunteers
- 22,111 people
- Sponsor
- St. Olavs Hospital
Intracranial Hemorrhage, Traumatic, Embolism and Thrombosis
Traumatic Intracranial Hemorrhage in Users of Oral Antithrombotic Drugs
Oral antithrombotic medications (OAM) are used for the prevention and treatment of thrombotic disorders. Among hemorrhagic complications of OAMs, intracranial hemorrhage (ICH) may have particularly devastating consequences with…
- Conditions
- Intracranial Hemorrhage, Traumatic, Embolism and Thrombosis, Hematoma, Subdural, Intracranial
- Trial name
- NCT02996851
- Volunteers
- 6,279 people
- Sponsor
- St. Olavs Hospital
Ischemic Stroke, Adverse Effect of Thrombolytic Drugs, Sequela
Hospital Processes Reengineering of Intravenous Thrombolysis in Acute Ischemic Stroke in China
PROMISE is a prospective, nationwide, multicenter, longitudinal cohort study, focusing on hospital intravenous thrombolysis process reengineering for acute ischemic stroke (AIS).
- Trial name
- PROMISE (NCT02631317)
- Testing
- Advance hospital notification by EMS, stroke team notification, key performance indicators feedback form
- Volunteers
- 2,178 people
- Sponsor
- First Affiliated Hospital of Jinan University
Brain Ischemia, Adverse Effect of Thrombolytic Drugs
Pre-stroke Cognitive Status and Thrombolytic Therapy
At the acute stage of cerebral ischaemia, the only effective drug that increases the proportion of patients who survive without dependency is thrombolytic therapy by intravenous (i.v.) tissue-plasminogen activator (t-PA).
- Conditions
- Brain Ischemia, Adverse Effect of Thrombolytic Drugs, Impaired Cognition, Dementia
- Trial name
- OPHELIE-COG (NCT01713491)
- Where
- 9 sites in France, Japan
- Volunteers
- 205 people
- Sponsor
- University Hospital, Lille